Latest Biotech News

Page 4 of 42
Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.
Ada Torres
Ada Torres
28 Aug 2026
Papyrus Australia has expanded its TBS contract for an additional sample run after mixed trial results and secured a $200,000 unsecured loan with Irwin Biotech, advancing its capital raising efforts with L39 Capital.
Victor Sage
Victor Sage
28 Aug 2026
Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.
Ada Torres
Ada Torres
28 Aug 2026
Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.
Ada Torres
Ada Torres
27 Aug 2026
Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.
Ada Torres
Ada Torres
27 Aug 2026
Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.
Victor Sage
Victor Sage
27 Aug 2026
Associate Global Partners (ASX:APL) reported a 20% rise in funds under management to $1.672 billion for FY2026, driven by strong inflows and new partnerships with Muzinich and ARK Invest.
Claire Turing
Claire Turing
26 Aug 2026
Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.
Ada Torres
Ada Torres
26 Aug 2026
Prescient Therapeutics (ASX:PTX) has opened a $7 million Share Purchase Plan at a significant discount to advance its lead cancer therapy PTX-100 beyond a pivotal Dose Optimisation Committee review in late 2026.
Ada Torres
Ada Torres
26 Aug 2026
Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.
Ada Torres
Ada Torres
25 Aug 2026
Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.
Ada Torres
Ada Torres
25 Aug 2026
Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.
Ada Torres
Ada Torres
25 Aug 2026

Browse the archive

Full archive